Largest biotech by earnings
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Gilead Sciences leads the 24 biotech ranked by earnings, at CHF 7.2B, ahead of Amgen (CHF 6.5B) and Biogen (CHF 1.1B). Figures as of 18 Nov 2026, 15:06 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesCHF 7.2B
- Median
- -CHF 57.8M
- Combined market value
- CHF 715.9B
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Earnings ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | CHF 7.2B | CHF 177.5B | CHF 143.14 | 0.22% down | 33% up | ||
| 2 | AmgenAMGN · Health Care | CHF 6.5B | CHF 206.3B | CHF 381.34 | 1.17% down | 34% up | ||
| 3 | BiogenBIIB · Health Care | CHF 1.1B | CHF 31.3B | CHF 211.49 | 0.08% up | 49% up | ||
| 4 | argenxARGX · Health Care | CHF 1.1B | CHF 51B | CHF 811.42 | 1.64% up | 4% up | ||
| 5 | ExelixisEXEL · Health Care | CHF 659.4M | CHF 14.2B | CHF 58.31 | 1.04% up | 63% up | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | CHF 403.3M | CHF 14B | CHF 138.19 | 1.15% down | 20% up | ||
| 7 | QiagenQGEN · Health Care | CHF 358M | CHF 8.6B | CHF 41.88 | 0.09% down | 12% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | CHF 267M | CHF 9.3B | CHF 81.87 | 1.25% up | 37% up | ||
| 9 | Krystal BiotechKRYS · Health Care | CHF 172.6M | CHF 7.7B | CHF 260.42 | 3.53% up | 46% up | ||
| 10 | Bio-TechneTECH · Health Care | CHF 153.2M | CHF 9.6B | CHF 61.28 | 0.14% up | 26% up | ||
| 11 | RepligenRGEN · Health Care | CHF 41.2M | CHF 9.3B | CHF 145.89 | 6.76% up | 5% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | -CHF 50.1M | CHF 4B | CHF 24.46 | 1.90% up | 88% up | ||
| 13 | Twist BioscienceTWST · Health Care | -CHF 65.4M | CHF 6.8B | CHF 99.67 | 5.62% up | 340% up | ||
| 14 | CG OncologyCGON · Health Care | -CHF 135.6M | CHF 5.8B | CHF 65.30 | 1.82% down | 85% up | ||
| 15 | Kodiak SciencesKOD · Health Care | -CHF 193.8M | CHF 5.5B | CHF 83.41 | 2.27% up | 396% up | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | -CHF 262.3M | CHF 8.9B | CHF 104.18 | 1.75% up | 87% up | ||
| 17 | ImmunityBioIBRX · Health Care | -CHF 296.1M | CHF 5.9B | CHF 5.50 | 4.36% up | 193% up | ||
| 18 | Scholar Rock HoldingSRRK · Health Care | -CHF 318.4M | CHF 4.9B | CHF 40.23 | 5.92% up | 14% up | ||
| 19 | ImmunovantIMVT · Health Care | -CHF 426M | CHF 5.9B | CHF 28.43 | 1.60% up | 43% up | ||
| 20 | CRISPR TherapeuticsCRSP · Health Care | -CHF 490M | CHF 3.4B | CHF 35.54 | 5.07% up | 21% down | ||
| 21 | VaxcytePCVX · Health Care | -CHF 645.9M | CHF 7.9B | CHF 49.96 | 0.17% down | 22% up | ||
| 22 | Revolution MedicinesRVMD · Health Care | -CHF 953.2M | CHF 29.5B | CHF 136.30 | 0.57% down | 131% up | ||
| 23 | BioNTechBNTX · Health Care | -CHF 1.1B | CHF 17.7B | CHF 71.59 | 0.13% up | 16% down | ||
| 24 | ModernaMRNA · Health Care | -CHF 2.4B | CHF 70.8B | CHF 174.89 | 0.37% up | 755% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Earnings is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8426 CHF).
Questions and answers
Which biotech rank first by earnings?
Gilead Sciences (CHF 7.2B), Amgen (CHF 6.5B) and Biogen (CHF 1.1B) are the top three of the 24 biotech ranked by earnings as of 18 Nov 2026, 15:06 UTC.
How many biotech are in this ranking?
24 are ranked by earnings.
What are these biotech worth together?
The 24 biotech ranked by earnings have a combined market value of CHF 715.9B as of 18 Nov 2026, 15:06 UTC.
What does ranking by earnings measure?
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech by earnings”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=earnings
Underlying data: Yahoo Finance; SEC EDGAR.